{"id":177562,"date":"2021-01-25T12:00:27","date_gmt":"2021-01-25T12:00:27","guid":{"rendered":"https:\/\/www.transcend.org\/tms\/?p=177562"},"modified":"2025-01-10T15:08:49","modified_gmt":"2025-01-10T15:08:49","slug":"meet-the-50-doctors-scientists-and-healthcare-entrepreneurs-who-became-pandemic-billionaires-in-2020","status":"publish","type":"post","link":"https:\/\/www.transcend.org\/tms\/2021\/01\/meet-the-50-doctors-scientists-and-healthcare-entrepreneurs-who-became-pandemic-billionaires-in-2020\/","title":{"rendered":"Meet the 50 Doctors, Scientists and Healthcare Entrepreneurs Who Became Pandemic Billionaires in 2020"},"content":{"rendered":"
\"\"<\/a>

From left to right: Moderna CEO St\u00e9phane Bancel, Stevanato Group president Sergio Stevanato, and BioNTech CEO U\u011fur \u015eahin.
Illustration by Forbes; photos, from left: Bertrand Guay\/AFP\/Getty Images; Stevanato Group; Andreas Arnold\/DPA\/Getty Images<\/p><\/div>\n

Dec 2020 – <\/em>Nearly a year after the first case of Covid-19 was reported in the Chinese city of Wuhan in December 2019, the world could be nearing the beginning of the end of a pandemic<\/a> that has killed more than 2 million people [in Jan 2021]. Vaccination for Covid-19 is underway in the United States and the United Kingdom, and promising antibody treatments could help doctors fight back against the disease more effectively. Tied to those breakthroughs: a host of new billionaires who have emerged in 2020, their fortunes propelled by a stock market surge as investors flocked to companies involved in the development of vaccines, treatments, medical devices and everything in between.<\/p>\n

Altogether, Forbes<\/em> found 50 new billionaires in the healthcare sector in 2020. The most notable newcomers of the year are the scientists behind the two most successful vaccines for the coronavirus\u00a0 \u2014 one developed by Pfizer and German biotech firm BioNTech, the other by Massachusetts-based Moderna \u2014 who have seen their net worths skyrocket since January: U\u011fur \u015eahin<\/a> and St\u00e9phane Bancel<\/a>.<\/p>\n

Virtually unknown at the outset of 2020, both men are now billionaires several times over. BioNTech CEO \u015eahin, who cofounded the firm with \u00d6zlem T\u00fcreci, his wife and the firm\u2019s chief medical officer \u2014 she owns no shares in the company \u2014 is now worth $4.2 billion; his French counterpart at Moderna, St\u00e9phane Bancel, has a $4.1 billion fortune. Moderna\u2019s meteoric rise also produced two more billionaires among its earliest investors, Harvard professor Timothy Springer<\/a> and MIT scientist Robert Langer<\/a>. Those vaccines will require billions of glass vials to safely transport them \u2014 enter Italy\u2019s Sergio Stevanato<\/a>, a new billionaire and the majority shareholder in the privately-owned Stevanato Group, which is making glass vials for several dozen vaccine efforts around the world.<\/p>\n

It\u2019s not just vaccines: companies developing antibody treatments and drugs to help doctors fight the virus have also benefited from the market frenzy. Carl Hansen, the CEO of Canadian biotech outfit AbCellera, is now worth $2.9 billion after his company went public on December 11, fueled by the Food and Drug Administration\u2019s approval<\/a> last month of its antibody treatment developed with pharma giant Eli Lilly. Even the firms working behind the scenes to help larger companies test new drugs and devices have seen their stock prices reach new highs. August Troendle, the founder and CEO of Cincinnati-based contract research firm Medpace, is now worth $1.3 billion thanks to a nearly 70% jump in the company\u2019s shares since the beginning of the year.<\/p>\n

The new moguls hail from 11 different countries, but the majority live in China, the early epicenter of Covid-19, which is now home to nearly three dozen new<\/a> healthcare billionaires\u00a0 \u2014 chief among them is Hu Kun<\/a>, the chairman of medical device manufacturer Contec Medical Systems, which went public on the Shenzhen stock exchange in August. Contec\u2019s shares have risen nearly 150% since the IPO on the back of strong overseas sales of products ranging from pulse oximeters to pulmonary devices used for checking lung conditions, all of which have become more necessary with the spread of Covid-19 throughout the globe.<\/p>\n

Here are the 10 most noteworthy newcomers with ties to the fight against the pandemic, followed by the 40 other healthcare billionaires who emerged in 2020:<\/p>\n

U\u011fur \u015eahin<\/strong><\/a><\/p>\n

\n
\"BioNTech<\/div>
\n

BioNTech CEO U\u011fur \u015eahin – dpa\/picture alliance via Getty Images<\/small><\/strong><\/p>\n<\/figcaption><\/figure>\n

Net worth: $4.2 billion<\/p>\n

Citizenship: Germany<\/p>\n

Source of wealth: BioNTech<\/p>\n

The Turkish-born physician cofounded BioNTech in the German city of Mainz in 2008 with his wife, \u00d6zlem T\u00fcreci, who serves as the firm\u2019s Chief Medical Officer. He owns about 17% of the company\u2019s shares. BioNTech\u2019s stock has risen<\/a> 160% since January on the back of its successful Covid-19 vaccine developed in partnership with Pfizer, which was declared by the U.S. FDA to be 95% effective in preventing Covid-19. The first doses were rolled out in the U.K. on December 8th and in the U.S. on December 14th, with more doses reserved for the European Union, Japan and Canada, among others. Before starting BioNTech, \u015eahin and T\u00fcreci founded biopharma company Ganymed Pharmaceuticals in 2001, which they sold to Japan-based Astellas Pharma for about $460 million in 2016.<\/p>\n

St\u00e9phane Bancel<\/strong><\/a><\/p>\n

\n
\"Moderna<\/div>
\n

Moderna CEO St\u00e9phane Bancel. Getty Images<\/small><\/strong><\/p>\n<\/figcaption><\/figure>\n

Net worth: $4.1 billion<\/p>\n

Citizenship: France<\/p>\n

Source of wealth: Moderna<\/p>\n

Bancel, a French citizen, became CEO of Massachusetts-based Moderna in 2011 after leaving his previous job as CEO of French diagnostics firm BioM\u00e9rieux. He owns about 6% of Moderna, down from about 9% when he first became<\/a> a billionaire in March, after selling more than a million shares as the firm\u2019s stock surged by more than 550% since the beginning of the year. On December 18, Moderna\u2019s Covid-19 vaccine – with a reported efficacy of 95% \u2014 was the second to be approved by regulators in the U.S. after the Pfizer-BioNTech vaccine. The first doses will be administered<\/a> in the U.S., which ordered 200 million doses with an option for 300 million more.<\/p>\n

Yuan Liping<\/strong><\/a><\/p>\n

Net worth: $4.1 billion<\/p>\n

Citizenship: Canada<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Yuan owns 24% of one of China\u2019s leading vaccine producers, Shenzhen Kangtai Biological Products, after her divorce from the company\u2019s chairman (and fellow billionaire) Du Weimin<\/a> in June. The split instantly made the Shenzhen resident Canada\u2019s richest woman. Kangtai\u2019s stock is up 90% since the beginning of 2020. She worked at the company from 2012 to 2015 as a manager and director and has been a director at a Kangtai subsidiary, Beijing Minhai Biotechnology, since March 2017. Kangtai is the exclusive Chinese manufacturer for the vaccine developed by AstraZeneca and the University of Oxford, with a deal<\/a> to produce 200 million doses, but the company has a checkered history: in 2013, its hepatitis B vaccine was linked to the death of 17 infants, but a government investigation went nowhere and critics were reportedly<\/a> pressured to retract negative articles. A representative for Shenzhen Kangtai did not reply to a request for comment.<\/p>\n

Hu Kun<\/strong><\/a><\/p>\n

Net worth: $3.9 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical equipment<\/p>\n

Hu is the chairman of Contec Medical Systems, a manufacturer of medical devices based in the\u00a0 northeastern Chinese port city of Qinhuangdao. He took the company public on the Shenzhen stock exchange in August and owns nearly half of the shares, which are up nearly 150% since the IPO. Contec draws more than 70% of its revenue from overseas and makes a range of medical products for hospitals including nebulizers, stethoscopes and blood pressure monitors.<\/p>\n

Carl Hansen<\/strong><\/p>\n

Net worth: $2.9 billion<\/p>\n

Citizenship: Canada<\/p>\n

Source of wealth: AbCellera<\/p>\n

Hansen is the CEO and cofounder of Vancouver-based AbCellera, a biotech firm that uses<\/a> artificial intelligence and machine learning to identify the most promising antibody treatments for diseases. He founded the company in 2012. Until 2019 he also worked as a professor at the University of British Columbia, but shifted to focus full-time on AbCellera. That decision seems to have paid off, and Hansen\u2019s 23% stake earned him a spot in the billionaire club after AbCellera\u2019s successful listing on the Nasdaq on December 11. The U.S. government has ordered<\/a> 300,000 doses of bamlanivimab, an antibody AbCellera discovered in partnership with Eli Lilly that received FDA approval as a Covid-19 treatment in November.<\/p>\n

Timothy Springer<\/strong><\/a><\/p>\n

\n
\"Timothy<\/div>
\n

Timothy Springer. \u00a9 2018 Bloomberg Finance LP<\/small><\/strong><\/p>\n<\/figcaption><\/figure>\n

Net worth: $2 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Moderna<\/p>\n

An immunologist and professor of biological chemistry and molecular pharmacology at Harvard University, Springer was a founding investor in Moderna in 2010 when he put about $5 million into the fledgling company. A decade later, his 3.5% stake is now worth<\/a> roughly $1.6 billion. Springer is an active investor in biotech, with smaller holdings in publicly traded firms Scholar Rock and Morphic Therapeutic, which grew out of his research with postdoctoral students from his lab at Harvard. He earned his first big payday in 1999 when he sold LeukoSite, a biotech outfit he founded in 1993 and took public five years later, to Millennium Therapeutics for $635 million.<\/p>\n

Sergio Stevanato<\/strong><\/a><\/p>\n

Net worth: $1.8 billion<\/p>\n

Citizenship: Italy<\/p>\n

Source of wealth: Medical packaging<\/p>\n

Stevanato is president of Italian medical packaging firm Stevanato Group, the world\u2019s second-largest producer of glass vials and a prominent supplier<\/a> of vials for more than forty Covid-19 vaccines. Founded on the outskirts of Venice in 1949 by Sergio\u2019s father, Giovanni, the company is now run by Sergio\u2019s children, Franco and Marco, who serve as CEO and vice president, respectively. The $700 million (sales) company is also the world\u2019s largest producer of insulin pens and makes machines that craft, sterilize and package billions of vials, syringes and other glass products. In June, Stevanato signed an agreement with the Gates Foundation-backed Coalition for Epidemic Preparedness and Innovations to provide 100 million vials for nine different Covid-19 vaccines \u2014 since then, the firm has penned additional deals with several more vaccine manufacturers which it cannot publicly disclose.<\/p>\n

Robert Langer<\/strong><\/a><\/p>\n

\n
\"Robert<\/div>
\n

Robert Langer. Boston Globe via Getty Images<\/small><\/strong><\/p>\n<\/figcaption><\/figure>\n

Net worth: $1.5 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Moderna<\/p>\n

Known as the \u201cEdison of Medicine\u201d for his pioneering work in the field of biomedical engineering, Langer is a professor of chemical engineering at the Massachusetts Institute of Technology. He was a founding<\/a> investor in Moderna \u2014 located just across the street from his office in Cambridge \u2014 in 2010 and has never sold a share; his 3% stake is now worth about $1.5 billion. He owns smaller holdings in publicly traded biotech startups SQZ Biotechnologies and Frequency Therapeutics, both founded by postdoctoral students from his lab, and he holds more than 1,400 patents which have been licensed more than 400 times to pharmaceutical and medical companies.<\/p>\n

Premchand Godha<\/strong><\/a><\/p>\n

Net worth: $1.4 billion<\/p>\n

Citizenship: India<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Godha started out as a chartered accountant before entering the pharmaceutical sector in 1975, when he acquired Mumbai-based drugmaker Ipca Labs in partnership with the family of Bollywood superstar Amitabh Bachchan. The firm, which manufactures generics and pharmaceutical ingredients, saw its stock price nearly double this year partly due to higher production and sales of the controversial antimalarial drug hydroxychloroquine, which was touted as a potential cure early in the pandemic before its use was discouraged<\/a> by the World Health Organization for having little to no effect in reducing mortality from Covid-19.<\/p>\n

August Troendle<\/strong><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Pharmaceutical services<\/p>\n

Troendle is the CEO and founder of Cincinnati-based Medpace, which carries out contract work and clinical trials for pharmaceutical firms developing drugs and medical devices. Before founding Medpace in 1992 and taking it public in 2016, the University of Maryland-trained doctor worked on clinical development at Swiss pharma giant Novartis and as a medical review officer at the FDA. Medpace\u2019s labs handle the gamut of pharmaceutical services, from running swab and antibody tests for Covid-19 for external clinics to running complex clinical trials for drugmakers working on new vaccines and treatments. Forbes<\/em> estimates that Troendle, who owns about 21% of Medpace shares, is now worth about $1.3 billion, making him the latest healthcare entrepreneur to join the billionaire club in 2020.<\/p>\n

Li Juanquan & family<\/strong><\/a><\/p>\n

Net worth: $7.9 billion<\/p>\n

Citizenship: Hong Kong<\/p>\n

Source of wealth: Surgical products<\/p>\n

Jian Jun<\/strong><\/a><\/p>\n

Net worth: $4.4 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Biotech<\/p>\n

Ye Xiaoping<\/strong><\/a><\/p>\n

Net worth: $4.2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Hao Hong<\/strong><\/a><\/p>\n

Net worth: $3.4 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Jin Lei<\/strong><\/a><\/p>\n

Net worth: $3.2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Liu Fangyi<\/strong><\/a><\/p>\n

Net worth: $3.2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical equipment<\/p>\n

Lv Jianming<\/strong><\/a><\/p>\n

Net worth: $3.1 billion<\/p>\n

Citizenship: Hong Kong<\/p>\n

Source of wealth: Medical equipment<\/p>\n

Gan Zhongru<\/strong><\/a><\/p>\n

Net worth: $2.8 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Weng Xianding<\/strong><\/a><\/p>\n

Net worth: $2.8 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical devices<\/p>\n

Chen Xiao Ying<\/strong><\/a><\/p>\n

Net worth: $2.7 billion<\/p>\n

Citizenship: Hong Kong<\/p>\n

Source of wealth: Health information<\/p>\n

Xie Juhua & family<\/strong><\/a><\/p>\n

Net worth: $2.6 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Dai Lizhong<\/strong><\/a><\/p>\n

Net worth: $2.5 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical testing<\/p>\n

Miao Yongjun<\/strong><\/a><\/p>\n

Net worth: $2.5 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Clinical diagnostics<\/p>\n

Hu Gengxi & family<\/strong><\/a><\/p>\n

Net worth: $2.3 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Biopharma<\/p>\n

Li Zhibiao<\/strong><\/a><\/p>\n

Net worth: $2.3 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Personal care products<\/p>\n

Lin Zhixiong & family<\/strong><\/a><\/p>\n

Net worth: $2.1 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical devices<\/p>\n

Alberto Siccardi & family<\/strong><\/a><\/p>\n

Net worth: $2.1 billion<\/p>\n

Citizenship: Switzerland<\/p>\n

Source of wealth: Medical devices<\/p>\n

Gao Yi & family<\/strong><\/a><\/p>\n

Net worth: $2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Lin Zhijun<\/strong><\/a><\/p>\n

Net worth: $2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical devices<\/p>\n

Xie Liangzhi & family<\/strong><\/a><\/p>\n

Net worth: $2 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Biotech<\/p>\n

Chen Baohua<\/strong><\/a><\/p>\n

Net worth: $1.8 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Zhu Yiwen & family<\/strong><\/a><\/p>\n

Net worth: $1.8 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Healthcare services<\/p>\n

Li Wenmei & family<\/strong><\/a><\/p>\n

Net worth: $1.7 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical equipment<\/p>\n

Lin Jie & family<\/strong><\/a><\/p>\n

Net worth: $1.7 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Liu Xiucai & family<\/strong><\/a><\/p>\n

Net worth: $1.6 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Chemicals<\/p>\n

Pu Zhongjie & family<\/strong><\/a><\/p>\n

Net worth: $1.6 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical equipment<\/p>\n

Rao Wei & family<\/strong><\/a><\/p>\n

Net worth: $1.6 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Ren Jinsheng & family<\/strong><\/a><\/p>\n

Net worth: $1.6 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Xiong Jun & family<\/strong><\/a><\/p>\n

Net worth: $1.5 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Yi Xianzhong & family<\/strong><\/a><\/p>\n

Net worth: $1.5 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Felix Baker<\/strong><\/a><\/p>\n

Net worth: $1.4 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Biotech investing<\/p>\n

Julian Baker<\/strong><\/a><\/p>\n

Net worth: $1.4 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Biotech investing<\/p>\n

Rajendra Agarwal<\/strong><\/a><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: India<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Banwarilal Bawri<\/strong><\/a><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: India<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Girdharilal Bawri<\/strong><\/a><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: India<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Benedicte Find<\/strong><\/a><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: Denmark<\/p>\n

Source of wealth: Medical devices<\/p>\n

Alan Miller & family<\/strong><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: United States<\/p>\n

Source of wealth: Healthcare services<\/p>\n

Zhong Ming & family<\/strong><\/a><\/p>\n

Net worth: $1.3 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Medical instruments<\/p>\n

Yuan Jiandong & family<\/strong><\/a><\/p>\n

Net worth: $1.1 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

Fan Minhua<\/strong><\/a><\/p>\n

Net worth: $1.1 billion<\/p>\n

Citizenship: China<\/p>\n

Source of wealth: Pharmaceuticals<\/p>\n

_______________________________________________<\/p>\n

\"\"<\/a>Giacomo Tognini – I cover billionaires and their wealth for <\/em>Forbes. In the past, I’ve covered everything from oil & gas for <\/em>Bloomberg News to the 2014 Indonesian presidential election for the <\/em>Jakarta Globe. I’m a graduate of Columbia Journalism School and UC Berkeley, and my work has also appeared in the <\/em>Houston Chronicle, the<\/em> Calgary Herald, and more.<\/em><\/p>\n

Go to Original – forbes.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Forbes found 50 new billionaires in the healthcare sector in 2020. The most notable newcomers of the year are the scientists behind two vaccines for the coronavirus \u2014 one developed by Pfizer and German biotech firm BioNTech, the other by Moderna \u2014 who have seen their net worths skyrocket since Jan 2020.<\/p>\n","protected":false},"author":4,"featured_media":177565,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[887,1009,232,1829,1868,555,1864,304,1213],"class_list":["post-177562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-capitalism","tag-big-pharma","tag-big-tech","tag-capitalism","tag-coronavirus","tag-covid-19","tag-elites","tag-pandemic","tag-science","tag-super-rich"],"_links":{"self":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/177562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/comments?post=177562"}],"version-history":[{"count":1,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/177562\/revisions"}],"predecessor-version":[{"id":284847,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/177562\/revisions\/284847"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/media\/177565"}],"wp:attachment":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/media?parent=177562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/categories?post=177562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/tags?post=177562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}